NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Nova Scotia Health Authority
Eli Lilly and Company
M.D. Anderson Cancer Center
Sanofi
Sanofi
National Institutes of Health Clinical Center (CC)